Willis Towers Watson (WTW)
(Delayed Data from NSDQ)
$261.98 USD
+3.82 (1.48%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $261.91 -0.07 (-0.03%) 6:14 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
WTW 261.98 +3.82(1.48%)
Will WTW be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for WTW based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for WTW
Should You Buy Marsh & McLennan (MMC) Following Dividend Hike?
Here's Why Willis Towers (WTW) Stock is Worth Retaining
WTW: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Investors Should Retain Willis Towers (WTW) Now
The Zacks Analyst Blog Highlights JPMorgan Chase, Texas Instruments, Morgan Stanley, Ross Stores and Willis Towers Watson
Top Research Reports for JPMorgan Chase, Texas Instruments & Morgan Stanley
Other News for WTW
M&A optimism takes firmer hold as momentum continues to build
WTW to Announce Second Quarter Earnings on July 25, 2024
WTW announces leadership change in Australia and New Zealand to foster continued growth
WTW publishes second annual sustainability report
Cost of new drug development is key concern for life science as focus shifts to repurposing